WO2022116943A1 - 取代的稠合双环化合物作为激酶抑制剂及其应用 - Google Patents
取代的稠合双环化合物作为激酶抑制剂及其应用 Download PDFInfo
- Publication number
- WO2022116943A1 WO2022116943A1 PCT/CN2021/134071 CN2021134071W WO2022116943A1 WO 2022116943 A1 WO2022116943 A1 WO 2022116943A1 CN 2021134071 W CN2021134071 W CN 2021134071W WO 2022116943 A1 WO2022116943 A1 WO 2022116943A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- methylpiperazin
- phenyl
- amino
- methoxy
- Prior art date
Links
- -1 bicyclic compound Chemical class 0.000 title claims abstract description 206
- 229940043355 kinase inhibitor Drugs 0.000 title abstract description 8
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 172
- 101000970023 Homo sapiens NUAK family SNF1-like kinase 1 Proteins 0.000 claims abstract description 51
- 102100021732 NUAK family SNF1-like kinase 1 Human genes 0.000 claims abstract description 51
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 30
- 201000011510 cancer Diseases 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 16
- 230000001404 mediated effect Effects 0.000 claims abstract description 15
- 208000035475 disorder Diseases 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 125000001424 substituent group Chemical group 0.000 claims description 71
- 125000000623 heterocyclic group Chemical group 0.000 claims description 67
- 150000002367 halogens Chemical class 0.000 claims description 65
- 229910052736 halogen Inorganic materials 0.000 claims description 63
- 229910052739 hydrogen Inorganic materials 0.000 claims description 62
- 229910052799 carbon Inorganic materials 0.000 claims description 61
- 229910052757 nitrogen Inorganic materials 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 40
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 32
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 31
- 239000002246 antineoplastic agent Substances 0.000 claims description 28
- 229940041181 antineoplastic drug Drugs 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 229940002612 prodrug Drugs 0.000 claims description 22
- 239000000651 prodrug Substances 0.000 claims description 22
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 239000012453 solvate Substances 0.000 claims description 20
- 125000004193 piperazinyl group Chemical group 0.000 claims description 19
- 125000003386 piperidinyl group Chemical group 0.000 claims description 18
- 125000003566 oxetanyl group Chemical group 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 125000002757 morpholinyl group Chemical group 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 12
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 12
- 125000002619 bicyclic group Chemical group 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 10
- 150000004677 hydrates Chemical class 0.000 claims description 10
- 125000005960 1,4-diazepanyl group Chemical group 0.000 claims description 9
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims description 8
- 229960004641 rituximab Drugs 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 6
- LLJZXKCGHUTJBF-UHFFFAOYSA-N CN(CC1)CCN1C(C=C1)=CC(OC)=C1NC(N=C1)=NC(N2C3CCCC3)=C1N=CC2=O Chemical compound CN(CC1)CCN1C(C=C1)=CC(OC)=C1NC(N=C1)=NC(N2C3CCCC3)=C1N=CC2=O LLJZXKCGHUTJBF-UHFFFAOYSA-N 0.000 claims description 6
- RZASDXHTLHNCFE-UHFFFAOYSA-N CN(CC1)CCN1C(C=C1)=CC(OC)=C1NC1=NC(C(C2=CCCC2)=CN=C2)=C2C=N1 Chemical compound CN(CC1)CCN1C(C=C1)=CC(OC)=C1NC1=NC(C(C2=CCCC2)=CN=C2)=C2C=N1 RZASDXHTLHNCFE-UHFFFAOYSA-N 0.000 claims description 6
- AQCDQUJTAZQZHN-UHFFFAOYSA-N CN(CC1)CCN1C(C=C1)=CC(OC)=C1NC1=NC(N(C2CCCC2)C(CC2)=O)=C2C=N1 Chemical compound CN(CC1)CCN1C(C=C1)=CC(OC)=C1NC1=NC(N(C2CCCC2)C(CC2)=O)=C2C=N1 AQCDQUJTAZQZHN-UHFFFAOYSA-N 0.000 claims description 6
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 claims description 6
- 229960001433 erlotinib Drugs 0.000 claims description 6
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- 229960002450 ofatumumab Drugs 0.000 claims description 6
- ZIEMCZRWHOFOOF-UHFFFAOYSA-N CN(CC1)CCN1C(C=C1)=CC(OC)=C1NC(N=C1)=NC(N2C3CCCC3)=C1OCC2=O Chemical compound CN(CC1)CCN1C(C=C1)=CC(OC)=C1NC(N=C1)=NC(N2C3CCCC3)=C1OCC2=O ZIEMCZRWHOFOOF-UHFFFAOYSA-N 0.000 claims description 5
- JONCKRYGMFWTNB-UHFFFAOYSA-N CN(CC1)CCN1C(C=C1)=CC(OC)=C1NC1=NC(C(C2CCCC2)=CN=C2)=C2C=N1 Chemical compound CN(CC1)CCN1C(C=C1)=CC(OC)=C1NC1=NC(C(C2CCCC2)=CN=C2)=C2C=N1 JONCKRYGMFWTNB-UHFFFAOYSA-N 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 125000002393 azetidinyl group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229940022353 herceptin Drugs 0.000 claims description 5
- DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 claims description 4
- XJGXCBHXFWBOTN-UHFFFAOYSA-N 4-[[4-fluoro-3-[2-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[1,5-a]pyrazine-7-carbonyl]phenyl]methyl]-2h-phthalazin-1-one Chemical compound C1CN2N=C(C(F)(F)F)N=C2CN1C(=O)C1=CC(CC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F XJGXCBHXFWBOTN-UHFFFAOYSA-N 0.000 claims description 4
- VBTUJTGLLREMNW-UHFFFAOYSA-N 5-fluoro-1-[[4-fluoro-3-(4-pyrimidin-2-ylpiperazine-1-carbonyl)phenyl]methyl]quinazoline-2,4-dione Chemical compound FC1=CC=C(CN2C(NC(=O)C3=C(F)C=CC=C32)=O)C=C1C(=O)N(CC1)CCN1C1=NC=CC=N1 VBTUJTGLLREMNW-UHFFFAOYSA-N 0.000 claims description 4
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 229960001611 alectinib Drugs 0.000 claims description 4
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 claims description 4
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 229960001346 nilotinib Drugs 0.000 claims description 4
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 4
- 229950011068 niraparib Drugs 0.000 claims description 4
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims description 4
- 229960000572 olaparib Drugs 0.000 claims description 4
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 4
- 229950007072 pamiparib Drugs 0.000 claims description 4
- 229940073458 senaparib Drugs 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 4
- 229950004550 talazoparib Drugs 0.000 claims description 4
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 3
- VOXBZHOHGGBLCQ-UHFFFAOYSA-N 2-amino-3,7-dihydropurine-6-thione;hydrate Chemical compound O.N1C(N)=NC(=S)C2=C1N=CN2.N1C(N)=NC(=S)C2=C1N=CN2 VOXBZHOHGGBLCQ-UHFFFAOYSA-N 0.000 claims description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 3
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 3
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 3
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 3
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 3
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 108010016076 Octreotide Proteins 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- 229960005310 aldesleukin Drugs 0.000 claims description 3
- 108700025316 aldesleukin Proteins 0.000 claims description 3
- 229960000548 alemtuzumab Drugs 0.000 claims description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 3
- 229910052785 arsenic Inorganic materials 0.000 claims description 3
- 229940091658 arsenic Drugs 0.000 claims description 3
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims description 3
- 229940120638 avastin Drugs 0.000 claims description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 3
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002707 bendamustine Drugs 0.000 claims description 3
- 229960000397 bevacizumab Drugs 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 3
- 229960003008 blinatumomab Drugs 0.000 claims description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 3
- 229960001467 bortezomib Drugs 0.000 claims description 3
- 229960002092 busulfan Drugs 0.000 claims description 3
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 3
- 229960001573 cabazitaxel Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
- 229940127093 camptothecin Drugs 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 3
- 229960002438 carfilzomib Drugs 0.000 claims description 3
- 108010021331 carfilzomib Proteins 0.000 claims description 3
- 229960001602 ceritinib Drugs 0.000 claims description 3
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims description 3
- 229960005395 cetuximab Drugs 0.000 claims description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 3
- 229960004630 chlorambucil Drugs 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- 229960001338 colchicine Drugs 0.000 claims description 3
- 229960005061 crizotinib Drugs 0.000 claims description 3
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229960000684 cytarabine Drugs 0.000 claims description 3
- 229960002204 daratumumab Drugs 0.000 claims description 3
- 229960002448 dasatinib Drugs 0.000 claims description 3
- 229960001251 denosumab Drugs 0.000 claims description 3
- 229960004497 dinutuximab Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- 229960004137 elotuzumab Drugs 0.000 claims description 3
- 229960001904 epirubicin Drugs 0.000 claims description 3
- 229960005167 everolimus Drugs 0.000 claims description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 3
- 229960000390 fludarabine Drugs 0.000 claims description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- 229960002258 fulvestrant Drugs 0.000 claims description 3
- 229960002584 gefitinib Drugs 0.000 claims description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 229960005277 gemcitabine Drugs 0.000 claims description 3
- 229960001101 ifosfamide Drugs 0.000 claims description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 3
- 229960002411 imatinib Drugs 0.000 claims description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 3
- 229960005386 ipilimumab Drugs 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 3
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims description 3
- 229960002014 ixabepilone Drugs 0.000 claims description 3
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims description 3
- 229960003648 ixazomib Drugs 0.000 claims description 3
- 229960004891 lapatinib Drugs 0.000 claims description 3
- 229960004942 lenalidomide Drugs 0.000 claims description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 3
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 3
- 229960003881 letrozole Drugs 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 3
- 229960001924 melphalan Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960004857 mitomycin Drugs 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 229960003347 obinutuzumab Drugs 0.000 claims description 3
- 229960002700 octreotide Drugs 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 229960004390 palbociclib Drugs 0.000 claims description 3
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 229960001972 panitumumab Drugs 0.000 claims description 3
- 229960005184 panobinostat Drugs 0.000 claims description 3
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims description 3
- 229960000639 pazopanib Drugs 0.000 claims description 3
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 229960005079 pemetrexed Drugs 0.000 claims description 3
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 3
- 229960002087 pertuzumab Drugs 0.000 claims description 3
- 229960000214 pralatrexate Drugs 0.000 claims description 3
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 229960002633 ramucirumab Drugs 0.000 claims description 3
- 229930002330 retinoic acid Natural products 0.000 claims description 3
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 3
- 229960003452 romidepsin Drugs 0.000 claims description 3
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims description 3
- 108010091666 romidepsin Proteins 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 229960003787 sorafenib Drugs 0.000 claims description 3
- 229960001796 sunitinib Drugs 0.000 claims description 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 229960004964 temozolomide Drugs 0.000 claims description 3
- 229960003433 thalidomide Drugs 0.000 claims description 3
- 229960003087 tioguanine Drugs 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- 229960000575 trastuzumab Drugs 0.000 claims description 3
- 229960001727 tretinoin Drugs 0.000 claims description 3
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims description 3
- 229960001183 venetoclax Drugs 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 3
- 229960002066 vinorelbine Drugs 0.000 claims description 3
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 3
- 229960000237 vorinostat Drugs 0.000 claims description 3
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 3
- 229960004276 zoledronic acid Drugs 0.000 claims description 3
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 2
- 230000001919 adrenal effect Effects 0.000 claims description 2
- 229960002756 azacitidine Drugs 0.000 claims description 2
- 239000012830 cancer therapeutic Substances 0.000 claims description 2
- 208000002458 carcinoid tumor Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000001054 cortical effect Effects 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 102000055277 human IL2 Human genes 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 2
- 208000037244 polycythemia vera Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 229960001686 afatinib Drugs 0.000 claims 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 2
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims 2
- 229950004707 rucaparib Drugs 0.000 claims 2
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims 2
- 229960001612 trastuzumab emtansine Drugs 0.000 claims 2
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims 1
- 229960000455 brentuximab vedotin Drugs 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 235000013557 nattō Nutrition 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 47
- 239000003112 inhibitor Substances 0.000 abstract description 18
- 238000006243 chemical reaction Methods 0.000 description 94
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 67
- 239000000243 solution Substances 0.000 description 67
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 239000000047 product Substances 0.000 description 44
- 239000012043 crude product Substances 0.000 description 37
- 230000002829 reductive effect Effects 0.000 description 34
- 239000007787 solid Substances 0.000 description 29
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 27
- 102100021733 NUAK family SNF1-like kinase 2 Human genes 0.000 description 26
- 239000012074 organic phase Substances 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 101000970025 Homo sapiens NUAK family SNF1-like kinase 2 Proteins 0.000 description 24
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 125000000217 alkyl group Chemical group 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 16
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 16
- LUYPGLRYFIVYTH-UHFFFAOYSA-N 2-methoxy-4-(4-methylpiperazin-1-yl)aniline Chemical compound C1=C(N)C(OC)=CC(N2CCN(C)CC2)=C1 LUYPGLRYFIVYTH-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 13
- 238000010898 silica gel chromatography Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 11
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 239000004698 Polyethylene Substances 0.000 description 10
- 125000002252 acyl group Chemical group 0.000 description 10
- 238000006555 catalytic reaction Methods 0.000 description 10
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 238000010189 synthetic method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 239000007791 liquid phase Substances 0.000 description 8
- USRSXLSCBCEIRW-UHFFFAOYSA-N 8-cyclopentyl-2-methylsulfanyl-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C12=NC(SC)=NC=C2CNC(=O)N1C1CCCC1 USRSXLSCBCEIRW-UHFFFAOYSA-N 0.000 description 7
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 102000001253 Protein Kinase Human genes 0.000 description 6
- HKGVZNNJDXEJQC-UHFFFAOYSA-N [4-(cyclopentylamino)-2-methylsulfanylpyrimidin-5-yl]methanol Chemical compound CSC1=NC=C(CO)C(NC2CCCC2)=N1 HKGVZNNJDXEJQC-UHFFFAOYSA-N 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical group NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- CHSDJDLAKKAWCI-UHFFFAOYSA-N hth-01-015 Chemical compound N1=C2N(C)C3=CC4=CC=CC=C4C=C3C(=O)N(C)C2=C(C)N=C1NC(=C1)C=NN1C1CCNCC1 CHSDJDLAKKAWCI-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 108060006633 protein kinase Proteins 0.000 description 6
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 5
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229950006790 adenosine phosphate Drugs 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 4
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- DIVUXBABVYOIOT-UHFFFAOYSA-N 5-bromo-2-chloro-n-cyclopentylpyrimidin-4-amine Chemical compound ClC1=NC=C(Br)C(NC2CCCC2)=N1 DIVUXBABVYOIOT-UHFFFAOYSA-N 0.000 description 4
- HJQCAEDIUJXGCQ-UHFFFAOYSA-N 6-bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(Cl)=NC=C2C(C)=C(Br)C(=O)N1C1CCCC1 HJQCAEDIUJXGCQ-UHFFFAOYSA-N 0.000 description 4
- UDTZHILTPAKHBR-UHFFFAOYSA-N 8-cyclopentyl-2-methylsulfinylpyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(S(=O)C)=NC=C2C=CC(=O)N1C1CCCC1 UDTZHILTPAKHBR-UHFFFAOYSA-N 0.000 description 4
- 235000019489 Almond oil Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000008168 almond oil Substances 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 125000006823 (C1-C6) acyl group Chemical group 0.000 description 3
- QKRVSWPBAOCWHY-UHFFFAOYSA-N 4-(cyclopentylamino)-2-methylsulfanylpyrimidine-5-carbaldehyde Chemical compound CSC1=NC=C(C=O)C(NC2CCCC2)=N1 QKRVSWPBAOCWHY-UHFFFAOYSA-N 0.000 description 3
- VYGFIZHPKQIHMZ-UHFFFAOYSA-N 5-(aminomethyl)-n-cyclopentyl-2-methylsulfanylpyrimidin-4-amine Chemical compound CSC1=NC=C(CN)C(NC2CCCC2)=N1 VYGFIZHPKQIHMZ-UHFFFAOYSA-N 0.000 description 3
- RQEOXBNFWFMQNB-UHFFFAOYSA-N 6-acetyl-2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C(C)(=O)C1=C(C2=C(N=C(N=C2)Cl)N(C1=O)C1CCCC1)C RQEOXBNFWFMQNB-UHFFFAOYSA-N 0.000 description 3
- STSHETKCOZLESG-UHFFFAOYSA-N 8-cyclopentyl-2-methylsulfinyl-5,6-dihydropyrimido[4,5-d]pyrimidin-7-one Chemical compound C12=NC(S(=O)C)=NC=C2CNC(=O)N1C1CCCC1 STSHETKCOZLESG-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 3
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001062093 Homo sapiens RNA-binding protein 15 Proteins 0.000 description 3
- 229910003827 NRaRb Inorganic materials 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 102100029244 RNA-binding protein 15 Human genes 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000012054 celltiter-glo Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- WZWFKDMNCUUWEE-UHFFFAOYSA-N ethyl 3-[4-(cyclopentylamino)-2-methylsulfanylpyrimidin-5-yl]prop-2-enoate Chemical compound CCOC(=O)C=CC1=CN=C(SC)N=C1NC1CCCC1 WZWFKDMNCUUWEE-UHFFFAOYSA-N 0.000 description 3
- MYJQMHHJSZBXNK-UHFFFAOYSA-N ethyl 4-(cyclopentylamino)-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1NC1CCCC1 MYJQMHHJSZBXNK-UHFFFAOYSA-N 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- ZTHHRSBDBPCCMZ-UHFFFAOYSA-N 2,4-dichloro-5-methoxypyrimidine Chemical compound COC1=CN=C(Cl)N=C1Cl ZTHHRSBDBPCCMZ-UHFFFAOYSA-N 0.000 description 2
- INUSQTPGSHFGHM-UHFFFAOYSA-N 2,4-dichloro-5-nitropyrimidine Chemical compound [O-][N+](=O)C1=CN=C(Cl)N=C1Cl INUSQTPGSHFGHM-UHFFFAOYSA-N 0.000 description 2
- BSKNQSYIDZUXQT-UHFFFAOYSA-N 2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(Cl)=NC=C2C(C)=CC(=O)N1C1CCCC1 BSKNQSYIDZUXQT-UHFFFAOYSA-N 0.000 description 2
- WCBURNWVRFRXTK-UHFFFAOYSA-N 2-chloro-n-cyclopentyl-5-nitropyrimidin-4-amine Chemical compound [O-][N+](=O)C1=CN=C(Cl)N=C1NC1CCCC1 WCBURNWVRFRXTK-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 2
- SIKXIUWKPGWBBF-UHFFFAOYSA-N 5-bromo-2,4-dichloropyrimidine Chemical compound ClC1=NC=C(Br)C(Cl)=N1 SIKXIUWKPGWBBF-UHFFFAOYSA-N 0.000 description 2
- BSRGXJLCDDVAMG-UHFFFAOYSA-N 8-iodo-2-methylsulfanylpyrido[4,3-d]pyrimidine Chemical compound C1=NC=C(I)C2=NC(SC)=NC=C21 BSRGXJLCDDVAMG-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 2
- MHAAEBRPTSBZGG-UHFFFAOYSA-N CN(CC1)CCN1C(C=C1)=CC(OC)=C1NC1=NC=C(CCC(O)=O)C(NC2CCCC2)=N1 Chemical compound CN(CC1)CCN1C(C=C1)=CC(OC)=C1NC1=NC=C(CCC(O)=O)C(NC2CCCC2)=N1 MHAAEBRPTSBZGG-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 102100024299 Maternal embryonic leucine zipper kinase Human genes 0.000 description 2
- 101710154611 Maternal embryonic leucine zipper kinase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 101710151812 NUAK family SNF1-like kinase 2 Proteins 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- 239000012661 PARP inhibitor Substances 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 101150003085 Pdcl gene Proteins 0.000 description 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 102100032771 Serine/threonine-protein kinase SIK1 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 239000012635 anticancer drug combination Substances 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229960003005 axitinib Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- IUEWAGVJRJORLA-HZPDHXFCSA-N bmn-673 Chemical compound CN1N=CN=C1[C@H]1C(NNC(=O)C2=CC(F)=C3)=C2C3=N[C@@H]1C1=CC=C(F)C=C1 IUEWAGVJRJORLA-HZPDHXFCSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940046044 combinations of antineoplastic agent Drugs 0.000 description 2
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N vinyl ethyl ether Natural products CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ABJFBJGGLJVMAQ-UHFFFAOYSA-N 1,4-dihydroquinoxaline-2,3-dione Chemical compound C1=CC=C2NC(=O)C(=O)NC2=C1 ABJFBJGGLJVMAQ-UHFFFAOYSA-N 0.000 description 1
- FBZPUJQSCVYPTG-UHFFFAOYSA-N 1,6-naphthyridine-3-carbonitrile Chemical compound C1=CN=CC2=CC(C#N)=CN=C21 FBZPUJQSCVYPTG-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FSKYZRCACCHDGR-UHFFFAOYSA-N 1h-pyrido[3,2-d]pyrimidin-4-one Chemical compound C1=CN=C2C(=O)N=CNC2=C1 FSKYZRCACCHDGR-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- HDSSNQFHRRRXFG-UHFFFAOYSA-N 2-ethoxy-4-(4-methylpiperazin-1-yl)aniline Chemical compound C1=C(N)C(OCC)=CC(N2CCN(C)CC2)=C1 HDSSNQFHRRRXFG-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- GUPGZURVZDIQPM-UHFFFAOYSA-N 2-oxoethyl acetate Chemical compound CC(=O)OCC=O GUPGZURVZDIQPM-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- IRGBROWUJHZCIN-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyaniline Chemical compound C1=C(N)C(OC(C)C)=CC(N2CCN(C)CC2)=C1 IRGBROWUJHZCIN-UHFFFAOYSA-N 0.000 description 1
- GZXJDOFLCMEPGA-UHFFFAOYSA-N 4-(cyclopentylamino)-2-methylsulfanylpyrimidine-5-carboxylic acid Chemical compound CSC1=NC=C(C(O)=O)C(NC2CCCC2)=N1 GZXJDOFLCMEPGA-UHFFFAOYSA-N 0.000 description 1
- MYNMNRVNVCHWIT-UHFFFAOYSA-N 4-chloro-2-methylsulfanylpyrimidine-5-carboxylic acid Chemical compound CSC1=NC=C(C(O)=O)C(Cl)=N1 MYNMNRVNVCHWIT-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- FOHUMFIQHBSPGD-UHFFFAOYSA-N 7-aminoisochromen-1-one Chemical compound C1=COC(=O)C2=CC(N)=CC=C21 FOHUMFIQHBSPGD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WDHAAJIGSXNPFO-UHFFFAOYSA-N 8h-pyrido[2,3-d]pyrimidin-7-one Chemical class N1=CN=C2NC(=O)C=CC2=C1 WDHAAJIGSXNPFO-UHFFFAOYSA-N 0.000 description 1
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
- 239000012827 ATM inhibitor Substances 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 102100040862 Dual specificity protein kinase CLK1 Human genes 0.000 description 1
- 102100040844 Dual specificity protein kinase CLK2 Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 101000749294 Homo sapiens Dual specificity protein kinase CLK1 Proteins 0.000 description 1
- 101000749291 Homo sapiens Dual specificity protein kinase CLK2 Proteins 0.000 description 1
- 101001059429 Homo sapiens MAP/microtubule affinity-regulating kinase 3 Proteins 0.000 description 1
- 101001059427 Homo sapiens MAP/microtubule affinity-regulating kinase 4 Proteins 0.000 description 1
- 101000687968 Homo sapiens Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Proteins 0.000 description 1
- 101100027299 Homo sapiens NUAK2 gene Proteins 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- 101001000061 Homo sapiens Protein phosphatase 1 regulatory subunit 12A Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000695043 Homo sapiens Serine/threonine-protein kinase BRSK1 Proteins 0.000 description 1
- 101000794043 Homo sapiens Serine/threonine-protein kinase BRSK2 Proteins 0.000 description 1
- 101001059443 Homo sapiens Serine/threonine-protein kinase MARK1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000709238 Homo sapiens Serine/threonine-protein kinase SIK1 Proteins 0.000 description 1
- 101000709250 Homo sapiens Serine/threonine-protein kinase SIK2 Proteins 0.000 description 1
- 101000654491 Homo sapiens Serine/threonine-protein kinase SIK3 Proteins 0.000 description 1
- 101000984551 Homo sapiens Tyrosine-protein kinase Blk Proteins 0.000 description 1
- 101000607909 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 1 Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 1
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100028920 MAP/microtubule affinity-regulating kinase 3 Human genes 0.000 description 1
- 102100028913 MAP/microtubule affinity-regulating kinase 4 Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100024262 Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 101100354317 Mus musculus Ptk6 gene Proteins 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- ORQJPWRNWPJVTJ-UHFFFAOYSA-N N1N=CC2=C1C1=C(N=CN2)C=CC=C1 Chemical class N1N=CC2=C1C1=C(N=CN2)C=CC=C1 ORQJPWRNWPJVTJ-UHFFFAOYSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 101710151814 NUAK family SNF1-like kinase 1 Proteins 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 description 1
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 description 1
- 102100036547 Protein phosphatase 1 regulatory subunit 12A Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102000002490 Rad51 Recombinase Human genes 0.000 description 1
- 108010068097 Rad51 Recombinase Proteins 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101150083487 SIK1 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100028623 Serine/threonine-protein kinase BRSK1 Human genes 0.000 description 1
- 102100029891 Serine/threonine-protein kinase BRSK2 Human genes 0.000 description 1
- 102100028921 Serine/threonine-protein kinase MARK1 Human genes 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100034377 Serine/threonine-protein kinase SIK2 Human genes 0.000 description 1
- 102100031445 Serine/threonine-protein kinase SIK3 Human genes 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 102100027053 Tyrosine-protein kinase Blk Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102100039865 Ubiquitin carboxyl-terminal hydrolase 1 Human genes 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 101150040313 Wee1 gene Proteins 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 230000007960 cellular response to stress Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- HFXKQSZZZPGLKQ-UHFFFAOYSA-N cyclopentamine Chemical group CNC(C)CC1CCCC1 HFXKQSZZZPGLKQ-UHFFFAOYSA-N 0.000 description 1
- 229960003263 cyclopentamine Drugs 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- SNNHLSHDDGJVDM-UHFFFAOYSA-N ethyl 4-chloro-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1Cl SNNHLSHDDGJVDM-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000007946 glucose deprivation Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 102000052958 human NUAK1 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229960005558 mertansine Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- 159000000018 pyrido[2,3-d]pyrimidines Chemical class 0.000 description 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
- AFHQSQTUSWXNCL-UHFFFAOYSA-N pyrimidin-5-ol Chemical compound OC1=CN=CN=C1.OC1=CN=CN=C1 AFHQSQTUSWXNCL-UHFFFAOYSA-N 0.000 description 1
- FREJAOSUHFGDBW-UHFFFAOYSA-N pyrimidine-5-carbaldehyde Chemical compound O=CC1=CN=CN=C1 FREJAOSUHFGDBW-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- RADGPXZWMLVDDP-UHFFFAOYSA-N tert-butyl 4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate Chemical compound C1=C(N)C(OC)=CC(N2CCN(CC2)C(=O)OC(C)(C)C)=C1 RADGPXZWMLVDDP-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Definitions
- AMPK Addenosine 5′-monophosphate (AMP)-activated protein kinase
- AMPK is an AMP-dependent protein kinase and a serine/threonine protein kinase. It plays an important role in the regulation of cellular energy metabolism balance, glucose and cholesterol metabolism, and cell proliferation. effect (Tiziana et al., 2015; Vincent et al., 2015).
- AMPK activity is mainly regulated by the intracellular AMP/ATP ratio (Sanz P et al., 2008). When the intracellular ATP concentration decreases, the elevated 5'-AMP activates AMPK.
- AMPK has a heterotrimeric structure consisting of a catalytic subunit ⁇ and two regulatory subunits ⁇ and ⁇ .
- AMPK is a substrate of the tumor suppressor kinase LKB1.
- Twelve AMPK-related kinases have been found to be structurally similar to AMPK ⁇ subunits, including BRSK1, BRSK2, NUAK1, NUAK2, QIK, QSK, SIK, MARK1, MARK2, MARK3, MARK4, and MELK. All of these kinases, except MELK, are specifically phosphorylated and activated by LKB1 at threonine 172, which corresponds to the catalytic subunit of AMPK (Sun et al., 2013).
- NUAK1 also known as AMPK related protein kinase 5 or ARK5
- NUAK2 also known as NUAK family SNF1-like kinase 2 or SNARK
- NUAK1 also known as AMPK related protein kinase 5 or ARK5
- NUAK2 also known as NUAK family SNF1-like kinase 2 or SNARK
- NUAK1 also known as AMPK related protein kinase 5 or ARK5
- NUAK2 also known as NUAK family SNF1-like kinase 2 or SNARK
- NUAK1 is a member of the AMPK-related kinase family discovered by Suzuki et al. in 2003. It consists of 661 amino acids and has a molecular weight of 74kD. NUAK1 is expressed in heart, kidney, liver, brain, and skeletal muscle, and is highly expressed in various cancer cells, including multiple myeloma. Studies have shown that NUAK1 and AKT signaling pathways are related, particularly to IGF-induced cell migration and invasion (Kusakai et al., 2004).
- NUAK1 is strongly associated with cancer cell production and survival, inhibits tumor cell apoptosis caused by glucose starvation and factors such as cytokines and TNF ⁇ (Atsushi et al., 2003), and is a major factor in AKT-dependent tumor survival and metastasis.
- NUAK1 is highly expressed in tumor cells such as breast cancer (LiuF et al., 2013), liver cancer (Cui J et al., 2013) and pancreatic cancer (HUANGX et al., 2014), and plays an important role in tumor metastasis and invasion, making it a Potential targets for the treatment of tumors.
- NUAK2 is the fourth member of the AMPK-related protein kinase family (Dmytro et al., 2012) and has an autophosphorylation function.
- the human NUAK2 gene is located on chromosome 1q32.1 and consists of 628 amino acids with a molecular weight of 69kD.
- NUAK2 is mainly localized in the nucleus, can be activated in response to cellular and surrounding environmental stress, and is an integral part of the cellular stress response.
- the activity regulation of NUAK1 is similar to that of AMPK, and its catalytic domain contains a highly conserved T-loop, which is shown to be activated by upstream kinases via phosphorylated threonine.
- phosphorylation of threonine at position 211 of NUAK1 by LKB1 or phosphorylation of serine at position 600 by AKT can activate the activity of NUAK1.
- Activated NUAK1 activity is 10-20-fold higher than basal levels (Lizcano et al., 2004).
- the activity regulation mechanism of NUAK2 is highly similar to that of AMPK.
- alkoxy refers to an oxy group substituted with the above-mentioned C 1 -C 10 alkyl, preferably C 1 -C 6 alkyl or C 1 -C 4 alkyl, such as methoxy, ethoxy and the like.
- the alkyl group in the alkoxy group is optionally substituted.
- Substituents for alkoxy include, but are not limited to, halogen, morpholino, amino, and carboxyl (including ester groups thereof), including alkylamino and dialkylamino.
- Amino as used herein may be represented by -NR'R", wherein R' and R" are each independently hydrogen, optionally substituted C1 - C10 alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; or R' and R" together with the N to which they are attached form an optionally substituted 4- to 7-membered cyclic amino group optionally containing one or more (eg 2, 3) additional heteroatoms selected from O, N and S.
- Preferred amino groups include NH2 , and at least one of R' and R" is a C1 - C6 alkyl (preferably C1 -C 4 alkyl) group.
- aryl refers to an aryl group by itself or as part of another group, a monocyclic, bicyclic or tricyclic aromatic group containing from 6 to 14 carbon atoms.
- Aryl groups can be substituted with one or more substituents described herein.
- carbocyclyl refers to a saturated or partially saturated cyclic hydrocarbon group consisting of carbon and hydrogen, including cycloalkyl and cycloalkenyl.
- Useful cycloalkyl groups are C3- C8cycloalkyl groups.
- Useful cycloalkenyl groups include C3 - C8 cycloalkenyl groups.
- Typical cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
- Typical cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.
- Carbocyclyl groups such as C3- C8cycloalkyl and C3 - C8cycloalkenyl may be substituted with one or more substituents described herein.
- Useful halogens or halogen groups include fluorine, chlorine, bromine and iodine.
- an alkyl, cycloalkyl, alkoxy, amido, carbonyl, heterocyclyl, aryl or heteroaryl group described in any of the embodiments herein may be replaced by a Substituent substitution by more than one (eg 1, 2, 3 or 4) selected from the group consisting of halogen, cyano, nitro, hydroxyl, carboxyl, C1 - C6 amido, C1 - C6 alkane Oxy group, aryloxy group, C 1 -C 6 alkyl group, C 1 -C 6 acyl group, C 6 -C 10 aryl group, C 3 -C 8 cycloalkyl group, heterocyclic group or heteroaryl group, carbonyl group and the like.
- substituents themselves are also optionally substituted. More preferred substituents include, but are not limited to, halogen, carbonyl, C1 - C6 amido, C1 - C6 alkoxy, C1 - C6 alkyl, and C1 - C6 acyl.
- the substituent when the substituent is a cycloalkyl, heterocyclyl, aryl or heteroaryl, the number of the heterocyclyl, aryl or heteroaryl substituent is usually 1 .
- the connection or substitution between the various groups of the present invention should satisfy the valence theory; unless otherwise specified, when the valence theory is not satisfied, it is usually filled with H.
- the circles in each structural formula represent that the number and position of double bonds satisfy the covalent bond theory.
- the present invention provides compounds represented by formula I or pharmaceutically acceptable salts, geometric isomers, enantiomers, diastereomers, racemates, isotopically labeled compounds, solvents Compound, Hydrate or Prodrug:
- D 1 is selected from N and CR 4 ;
- D 2 is selected from N and CR 5 ;
- D 3 is selected from N and CR 6 ;
- R 7 is selected from halogen, optionally substituted C 1 -C 6 alkyl and optionally substituted C 1 -C 6 alkoxy;
- the compound of formula I has the structure shown in formula Ia or Ib below:
- the substituents on ring A may be 1, 2 or 3, and the substituents may be selected from optionally substituted C1 - C6 alkanes base, optionally substituted C 1 -C 6 alkoxy, halogen, cyano, oxo, optionally substituted C 3 -C 7 cycloalkyl, optionally substituted heterocyclyl, optionally substituted C 1 -C 6 acyl and -NR a R b , wherein R a and R b are each independently H or C 1 -C 4 alkyl.
- the number of substituents can be 1-5, and the substituents can be selected from halogen, hydroxyl and -NR a R b , wherein R a and R b are each independently H or C 1 -C 4 alkyl.
- the heterocyclic group is preferably a 3-7 membered heterocyclic group, more preferably a 3-7 membered nitrogen and/or oxygen-containing heterocyclic group, including but not limited to azetidine, oxetanyl, oxygen Heterocyclopropyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, piperazinyl and piperidinyl and the like.
- the number of substituents may be 1, 2 or 3, and the substituents may be selected from halogen, C 1 -C 4 alkyl, halogenated C 1 -C 4 alkyl, C 1 - C4alkoxy , halogenated C1 - C4alkoxy , hydroxy, and -NRaRb , wherein Ra and Rb are each independently H or C1 - C4alkyl.
- R 0 is optionally substituted 3-7 membered heterocyclyl.
- Preferred heterocyclic groups are 3-6 membered nitrogen- and/or oxygen-containing heterocyclic groups, including azetidine, oxetanyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrole Alkyl, morpholinyl, piperazinyl and piperidinyl, etc.
- R8 is optionally substituted C1 - C6 alkyl, optionally substituted C1 - C6 alkoxy, optionally substituted C1- C6 alkylamino and optionally substituted heterocyclyl.
- the heterocyclic group is preferably a 4-7 membered nitrogen and/or oxygen-containing heterocyclic group, including azetidine, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholine group, piperazinyl, 1,4-diazepanyl (such as 1,4-diazepan-1-yl) and piperidinyl and the like.
- the substituents on R 8 may be 1-4 groups selected from the group consisting of C 1 -C 6 alkyl, hydroxy substituted C 1 -C 6 alkyl, halogenated C 1 -C 6 alkyl , C 1 -C 6 alkoxy, C 1 -C 6 acyl, heterocyclyl optionally substituted with 1-4 C 1 -C 6 alkyl groups (4-7 membered nitrogen-containing and/ or oxygen heterocyclyl), halogen, -NR a R b and hydroxy, wherein R a and R b are each independently H and C 1 -C 6 alkyl.
- the substituents on R 8 are 1, 2 or 3 substituents selected from hydroxy, halogen, C 1 -C 4 alkyl and haloC 1 -C 4 alkyl.
- R8 is 4-7 optionally substituted with 1 or 2 substituents selected from -NRaRb , C1 - C4alkyl and haloC1 - C4alkyl
- Membered nitrogen-containing heterocyclyl groups include azetidinyl, pyrrolidinyl, piperazinyl, 1,4-diazepanyl and piperidinyl.
- R8 is attached to D1 or to D2 to form a 4-7 membered heterocyclyl or 5-14 membered heteroaryl which may be substituted.
- Preferred 4-7 membered heterocyclyl groups include, but are not limited to, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, piperazinyl, 1,4-diazepanyl (eg 1,4 -diazepan-1-yl) and piperidinyl, etc.
- preferred 5-14 membered heteroaryl groups include, but are not limited to, furyl, pyranyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl , pyrazinyl, pyrimidinyl, pyridazinyl and indolizinyl, etc.
- the number of substituents may be 1, 2 or 3, and the substituents may be selected from C 1 -C 6 alkyl, C 1 -C 6 acyl, optionally 1-4 C 1 -C 6 alkyl substituted heterocyclyl (4-7 membered heterocyclyl as previously described), halogen, -NR a R b and hydroxy, wherein R a and R b are each independently H and C 1 -C 6 alkyl.
- Ring A is preferably a 6-membered nitrogen-containing heterocyclic group or a 6-membered nitrogen-containing heteroaryl group that may be substituted, more preferably, Ring A is fused to a fused containing B-containing heterocyclic group.
- the bicyclic ring formed by the aromatic rings of 1 , B 2 and B 3 together is selected from:
- * 1 and * 2 represent the attachment positions of the group to the rest of the compound R 0 and -NH;
- R 3 is H or C 1 -C 3 alkyl (preferably methyl);
- R 9 is H or C 1 -C 3 alkyl (preferably methyl);
- R 10 is H, C 1 -C 3 alkyl (preferably methyl), C 2 -C 4 acyl (preferably acetyl) or cyano;
- R 12 is H or C 1 - C3 alkyl (preferably methyl).
- the compounds of formula I, Ia and Ib have the structure shown in formula II (including formula IIa, formula IIb and formula IIc):
- R 0 , B 1 , B 2 , B 3 , D 1 , D 2 , D 3 , R 7 and R 8 are as described in formula I;
- a 1 is selected from N and CR 9 ;
- a 2 is selected from N and CR 10 ;
- a 3 is selected from O, S, NR 11 and CR 13 R' 13 ;
- a 4 is selected from O, S, NR 12 and CR 14 R' 14 ;
- R 9 and R 10 are each independently H, halogen, cyano, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 alkoxy, or optionally substituted C 1 -C 6 acyl ;
- Preferred heterocyclic groups are 3-6 membered nitrogen- and/or oxygen-containing heterocyclic groups, including azetidine, oxetanyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrole Alkyl, morpholinyl, piperazinyl and piperidinyl, etc.
- R 0 substituents When substituted, the number of R 0 substituents is 1, 2 or 3, and the substituents can be selected from halogen, C 1 -C 6 alkyl, halogenated C 1 -C 6 alkyl, hydroxyl, C 1 -C 6 Alkoxy, halogenated C 1 -C 6 alkoxy and -NR a R b , wherein R a and R b are each independently H or C 1 -C 4 alkyl.
- D 1 , D 2 and D 3 are each independently N or CH; or D 1 is CR 4 , D 2 is CR 5 , and D 3 is CR 6 .
- R 4 , R 5 and R 6 are each independently H, halogen and C 1 -C 4 alkyl.
- D 1 , D 2 and D 3 are all CH.
- R 7 is halogen, optionally substituted C 1- C 3 alkyl and optionally substituted C 1- C 3 alkoxy, preferably R 7 is halogen and optionally substituted methoxy.
- the number of substituents may be 1, 2, 3, 4 or 5, and the substituents may be independently selected from halogen, Hydroxyl and -NR a R b , where R a and R b are each independently H or C 1 -C 4 alkyl.
- R8 is optionally substituted C1 - C6 alkyl, optionally substituted C1 - C6 alkoxy, optionally substituted C1- C6 alkylamino and optionally substituted heterocyclyl.
- the number of substituents may be 1, 2 or 3, and the substituents may be selected from C 1 -C 6 alkyl, C 1 -C 6 acyl, optionally 1-4 C 1 -C 6 alkyl substituted heterocyclyl (4-7 membered heterocyclyl as previously described), halogen, -NR a R b and hydroxy, wherein R a and R b are each independently H and C 1 -C 6 alkyl.
- R 9 and R 10 when each of R 9 and R 10 is substituted with C 1 -C 6 alkyl, C 1 -C 6 alkoxy and C 1 -C 6 acyl, the number of substituents may be is 1, 2, 3, 4 or 5, and the substituents may be independently selected from halogen, hydroxy and -NR a R b , wherein R a and R b are each independently H or C 1 -C 4 alkyl.
- Preferred R 9 and R 10 are each independently H, C 1 -C 4 alkyl, CN or C 2 -C 4 acyl.
- a 1 and A 2 are each independently N, CH, C-CN, C-(C 1 -C 3 alkyl) or C-(C 2 -C 4 acyl).
- a 1 is N and A 2 is CR 10 , wherein R 10 is selected from H and C 1 -C 3 alkyl.
- a 1 is CR 9 and A 2 is N, wherein R 9 is selected from H and C 1 -C 3 alkyl.
- a 3 is selected from O, NR 11 and CR 13 R' 13
- a 4 is selected from O, NR 12 and CR 14 R' 14 ; preferably, A 3 is selected from O and CR 13 R' 13
- a 4 is selected from O, NR 12 and CR 14 R' 14 .
- R 11 , R 12 , R 13 , R' 13 , R 14 and R' 14 are each independently H or C 1 -C 3 alkyl; preferably R 11 and R 12 are both H, R 13 and R At least one of '13 is H, and at least one of R14 and R'14 is H.
- a 3 and A 4 are each independently O, CH 2 or NH.
- the fused bicyclic ring containing A 3 , A 4 , B 1 , B 2 and B 3 is selected from:
- R 0 is optionally substituted 3-7 membered heterocyclyl.
- Preferred heterocyclic groups are 3-6 membered nitrogen- and/or oxygen-containing heterocyclic groups, including azetidine, oxetanyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrole Alkyl, morpholinyl, piperazinyl and piperidinyl, etc.
- R 9 and R 10 when each of R 9 and R 10 is substituted with C 1 -C 6 alkyl, C 1 -C 6 alkoxy and C 1 -C 6 acyl, the number of substituents may be is 1, 2, 3, 4 or 5, and the substituents may be independently selected from halogen, hydroxy and -NR a R b , wherein R a and R b are each independently H or C 1 -C 4 alkyl.
- Preferred R 9 and R 10 are each independently H, C 1 -C 4 alkyl, CN or C 2 -C 4 acyl.
- examples of pharmaceutically acceptable salts include inorganic and organic acid salts such as hydrochloride, hydrobromide, phosphate, sulfate, citrate, lactate, tartrate, maleate, rich Maleate, mandelate, and oxalate; and inorganic and organic base salts formed with bases such as sodium hydroxy, tris(hydroxymethyl)aminomethane (TRIS, tromethamine), and N-methylglucamine .
- inorganic and organic acid salts such as hydrochloride, hydrobromide, phosphate, sulfate, citrate, lactate, tartrate, maleate, rich Maleate, mandelate, and oxalate
- inorganic and organic base salts formed with bases such as sodium hydroxy, tris(hydroxymethyl)aminomethane (TRIS, tromethamine), and N-methylglucamine .
- the present invention also includes all suitable isotopic variations of the compounds of the present invention or pharmaceutically acceptable salts thereof.
- Isotopic variation of a compound of the present invention or a pharmaceutically acceptable salt thereof refers to the substitution of at least one atom by an atom having the same atomic number but a different atomic mass than that normally found in nature.
- Isotopes that may be introduced into the compounds of the present invention or pharmaceutically acceptable salts thereof include, but are not limited to, isotopes of H, C, N and O, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 17 O, 18 O, 35 S, 18 F, 36 Cl and 125 I.
- Appropriate isotopic derivatives of the compounds of the present invention, or pharmaceutically acceptable salts thereof can be prepared by conventional techniques for appropriate isotopic derivatives of the compounds using appropriate reagents.
- the compounds of the present invention can be prepared using methods known to those skilled in the art or the novel methods of the present invention. Specifically, compounds of the present invention having formula I can be prepared as shown in the reaction examples in Reaction Scheme 1 . 4-Chloro-2-(methylthio)pyrimidine-5-carboxylic acid ethyl ester reacts with cyclopentylamine under the catalysis of triethylamine in dichloromethane at room temperature to give the product 4-(cyclopentylamino)-2 -(Methylthio)pyrimidine-5-carboxylate.
- 5-(Chloromethyl)-N-cyclopentyl-2-(methylthio)pyrimidin-4-amine was reacted with ammonia in tetrahydrofuran at room temperature to give the product 5-(aminomethyl)-N-ring Pentyl-2-(methylthio)pyrimidin-4-amine.
- 5-(Aminomethyl)-N-cyclopentyl-2-(methylthio)pyrimidin-4-amine was reacted with 1,1'-carbonyldiimidazole to give the ring-closed product 1-cyclopentyl-7-( methylthio)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one.
- the target compound 1-cyclohexyl-7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidine can be prepared by substituting cyclohexylamine for cyclopentylamine And[4,5-d]pyrimidin-2(1H)-one.
- Substituting cyclopentylamine with cyclohexylamine can give the target compound 8-cyclohexyl-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyridyl[ 2,3-d]pyrimidin-7(8H)-one.
- the target compound 8-cyclopropyl-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5 can be obtained by replacing cyclopentylamine with cyclopropylamine, 8-Dihydropyrido[2,3-d]pyrimidin-7(6H)-one.
- 6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one and tributyl(1-ethoxyethylene)tin in di Stille coupling reaction occurs under the catalysis of (tri-tert-butylphosphine)palladium, and then reacts with dilute hydrochloric acid to obtain the product 6-acetyl-2-chloro-8-cyclopentyl-5-methylpyrido[2,3 -d]pyrimidin-7(8H)-one.
- NUAK1/2 inhibitors are kinase inhibitors, particularly NUAK1/2 inhibitors.
- Formula I (including Formula II and Formula III) or pharmaceutically acceptable salts, geometric isomers, enantiomers, diastereomers, racemates, isotopically labeled compounds, solvates thereof , hydrate or prodrug can be used as a separate active ingredient for the treatment and prevention of NUAK1/2 mediated diseases, disorders and conditions; or for the preparation of medicaments for the treatment and prevention of NUAK1/2 mediated diseases, disorders and conditions ;
- NUAK1/2 inhibitor with other anticancer drugs including but not limited to DSB inducers (eg radiation), topoisomerase II inhibitors (eg etoposide, doxorubicin) and/or PARP inhibitors (eg, olaparib, niraparib, lucaparib, talazoparib, pamiparib, fluzoparib, and
- the NUAK1/2 mediated diseases, disorders and conditions include cancer.
- Cancer can be a solid tumor or hematological tumor, including but not limited to liver cancer, melanoma, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast cancer cancer, ovarian cancer, Wilms tumor, cervical cancer, testicular cancer, soft tissue sarcoma, primary macroglobulinemia, bladder cancer, chronic myeloid leukemia, primary brain cancer, malignant melanoma, non-small cell carcinoma Cell lung cancer, small cell lung cancer, gastric cancer, colon cancer, malignant pancreatic insulinoma, malignant carcinoid cancer, choriocarcinoma, mycosis fungoides, head and neck cancer, osteosarcoma, pancreatic cancer, acute myeloid leukemia, hair cells Leukemia, rhabdomyos
- the present invention provides a method of treating or preventing NUAK1/2 mediated diseases, disorders and conditions comprising administering to a subject in need thereof an effective amount of a compound of Formula I (including Formula II and Formula III) or a pharmaceutically acceptable amount thereof.
- a compound of Formula I including Formula II and Formula III
- the subject includes mammals, more specifically humans.
- the methods of treating or preventing NUAK1/2-mediated diseases, disorders, and conditions described herein further comprise concurrently or sequentially administering to a subject in need thereof a therapeutically effective amount of at least one known anticancer drug or its A pharmaceutically acceptable salt; the at least one known anticancer drug or a pharmaceutically acceptable salt thereof is as described in any of the embodiments herein.
- an effective amount of the pharmaceutical formulation is administered to a patient having one or more of these symptoms.
- the pharmaceutical formulation contains a therapeutically effective concentration of a compound of formula I (including formula II and III) formulated for oral, intravenous, topical or topical administration for the treatment of cancer and other diseases.
- the amount administered is that amount effective to ameliorate or eliminate one or more conditions.
- an effective amount is an amount sufficient to ameliorate or in some way alleviate symptoms associated with the disease.
- Such amounts can be administered as a single dose, or can be administered according to an effective therapeutic regimen.
- the amount administered may cure the disease, but the drug is usually given to improve the symptoms of the disease. Repeated dosing is generally required to achieve the desired symptomatic improvement.
- a pharmaceutical composition comprising a compound of formula I (including formula II and III) of the invention or a pharmaceutically acceptable salt, geometric isomer thereof as a NUAK1/2 inhibitor , enantiomers, diastereomers, racemates, isotopically labeled compounds, solvates, hydrates or prodrugs with a pharmaceutically acceptable carrier.
- Another embodiment of the present invention relates to a pharmaceutical composition effective for the treatment of cancer comprising a compound of formula I (including formula II and III) of the present invention or a pharmaceutically acceptable salt, geometric Isomers, enantiomers, diastereomers, racemates, isotopically labeled compounds, solvates, hydrates or prodrugs, with at least one known anticancer drug or an anticancer drug Medicinal salt.
- a pharmaceutical composition effective for the treatment of cancer comprising a compound of formula I (including formula II and III) of the present invention or a pharmaceutically acceptable salt, geometric Isomers, enantiomers, diastereomers, racemates, isotopically labeled compounds, solvates, hydrates or prodrugs, with at least one known anticancer drug or an anticancer drug Medicinal salt.
- the at least one known anticancer drug or a pharmaceutically acceptable salt thereof includes other anticancer drugs related to DNA damage and repair mechanisms, including PARP inhibitors olaparib, niraparib, Capanib, talazoparib, pamiparib, fluzoparib, and senaparib; HDAC inhibitors vorinostat, romidepsin, panobinostat, and belinostat, among others.
- the at least one known anticancer drug or a pharmaceutically acceptable salt thereof also includes other anticancer drugs related to cell division checkpoints, including CDK4/6 inhibitors such as palbociclib, ATM inhibitors, ATR inhibitors agents, Wee1 inhibitors, MYT1 inhibitors, DNA-PK inhibitors and more. And in combination with other targeted anticancer drugs, including USP1 inhibitors, PRMT5 inhibitors, Pol ⁇ inhibitors, RAD51 inhibitors, etc.
- the compounds of the present invention and at least one known anticancer drug can be administered together as a single pharmaceutical composition.
- the compounds of the present invention may also be administered separately from at least one known anticancer drug.
- the compound of the present invention and at least one known anticancer drug are administered approximately simultaneously, ie, all drugs are administered simultaneously or sequentially, as long as the compounds achieve therapeutic concentrations in the blood simultaneously.
- the compounds of the present invention and at least one known anticancer drug are administered according to respective dosage regimens, so long as the compounds achieve therapeutic concentrations in the blood.
- bioconjugates of the present invention are a bioconjugate comprising the compound of the present invention, which can effectively inhibit tumors as a kinase inhibitor.
- the bioconjugates of the present invention contain a compound of the present invention and at least one antibody known to have a medical effect, such as Herceptin or Rituxan, or a growth factor, such as EGF or FGF, or a cytokine, such as interleukin 2 or 4, or any molecule capable of binding to the cell surface, or consisting of them.
- the antibody and other molecules can deliver the compound to its target, making it an effective anticancer drug.
- This bioconjugate can also enhance the anticancer effect of medically useful antibodies such as Herceptin or Rituxan.
- Another embodiment of the present invention relates to a pharmaceutical composition that can effectively inhibit tumors, comprising a NUAK1/2 inhibitor represented by formula I (including formula II and formula III), or a pharmaceutically acceptable salt, geometric Isomers, enantiomers, diastereomers, racemates, solvates, hydrates or prodrugs, in combination therapy with radiotherapy.
- a NUAK1/2 inhibitor represented by formula I (including formula II and formula III)
- a pharmaceutically acceptable salt geometric Isomers, enantiomers, diastereomers, racemates, solvates, hydrates or prodrugs
- Another embodiment of the present invention relates to an effective pharmaceutical composition for post-operative cancer treatment, comprising a NUAK1/2 inhibitor represented by formula I (including formula II and formula III), or a pharmaceutically acceptable composition thereof. Accepted salts, geometric isomers, enantiomers, diastereomers, racemates, solvates, hydrates or prodrugs.
- the present invention also relates to a method of treating cancer in the mammal by surgical resection of the tumor followed by the use of the pharmaceutical composition of the present invention.
- compositions of the present invention include all pharmaceutical formulations containing the compounds of the present invention in amounts effective to achieve their intended purpose. Although each individual's needs will vary, one skilled in the art can determine the optimal dosage for each part of the pharmaceutical formulation.
- the compound, or a pharmaceutically acceptable salt thereof is administered orally to mammals daily in an amount of about 0.0025 to 50 mg/kg body weight. Preferably, however, it is administered orally at about 0.01 to 10 mg/kg per kg. If a known anticancer drug is also administered, the dose should be effective for its intended purpose. Optimal dosages of these known anticancer drugs are well known to those skilled in the art.
- a unit oral dose may contain about 0.01 to 50 mg, preferably about 0.1 to 10 mg, of a compound of the present invention.
- a unit dose may be administered one or more times, in one or more tablets per day, each tablet containing about 0.1 to 50 mg, suitably about 0.25 to 10 mg, of a compound of the present invention or a solvate thereof.
- the concentration of the compounds of the present invention may range from about 0.01 to 100 mg per gram of carrier.
- the compounds of the present invention can be administered as raw pharmaceutical products.
- the compounds of the present invention may also be administered as part of a suitable pharmaceutical formulation containing a pharmaceutically acceptable carrier including excipients and adjuvants.
- a pharmaceutically acceptable carrier including excipients and adjuvants.
- These pharmaceutically acceptable carriers facilitate the processing of the compounds into pharmaceutically acceptable pharmaceutical preparations.
- Preferred pharmaceutical formulations especially those for oral and preferred modes of administration, such as tablets, troches and capsules, and solutions suitable for injection or oral administration, comprise from about 0.01% to 99%, preferably from about 0.25% up to 75% of active compound plus excipients.
- the scope of the present invention also includes non-toxic pharmaceutically acceptable salts of the compounds of the present invention.
- Acid addition salts are formed by mixing a solution of a non-toxic pharmaceutically acceptable acid with a solution of a compound of the present invention.
- Such acids are, for example, hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid and the like.
- Base addition salts are formed by mixing a solution of a non-toxic pharmaceutically acceptable base with a solution of a compound of the present invention.
- the base is, for example, sodium hydroxide, potassium hydroxide, hydrogen choline, sodium carbonate, tris, N-methyl-glucamine, and the like.
- the pharmaceutical formulations of the present invention can be administered to any mammal so long as they can obtain the therapeutic effects of the compounds of the present invention.
- the most important of these mammals are humans and veterinary animals, although the invention is not intended to be so limited.
- the pharmaceutical formulations of the present invention can be administered by any route to achieve their intended purpose.
- administration can be by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intrathecal, intracranial, nasal or topical routes.
- oral administration can be performed.
- the dose of the drug will be determined based on the patient's age, health and weight, the type of concurrent therapy, the frequency of therapy, and the desired therapeutic benefit.
- the pharmaceutical formulations of the present invention can be manufactured in a known manner. For example, manufactured by conventional mixing, granulating, tableting, dissolving, or freeze-drying processes.
- solid excipients and active compounds can be combined and the mixture optionally ground. After adding suitable auxiliaries, if desired or necessary, the mixture of granules is processed to obtain tablets or dragee cores.
- auxiliaries are in particular fillers, such as sugars such as lactose or sucrose, mannitol or sorbitol; cellulose preparations and/or calcium phosphates, such as tricalcium phosphate or calcium hydrogen phosphate; and binders, such as starch pastes, including Corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone.
- fillers such as sugars such as lactose or sucrose, mannitol or sorbitol
- cellulose preparations and/or calcium phosphates such as tricalcium phosphate or calcium hydrogen phosphate
- binders such as starch pastes, including Corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrol
- disintegrants such as the starches mentioned above, can be added, as well as carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
- Adjuvants are especially flow conditioners and lubricants, for example, silica, talc, stearic acid or its salts, such as magnesium stearate or calcium stearate, and/or polyethylene glycols.
- dragee cores can be provided with a suitable coating that is resistant to gastric juices. For this purpose, concentrated sugar solutions can be used.
- This solution may contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, a lacquer solution and a suitable organic solvent or solvent mixture.
- suitable cellulose solutions such as cellulose acetate phthalate or hydroxypropyl methylcellulose phthalate can be used.
- Dyestuffs or pigments may be added to the coatings of the tablets or dragee cores. For example, for identification or to characterize combinations of active ingredient doses.
- compositions that can be taken orally include press-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol.
- the push-fit capsules can contain the active compounds in the form of granules in admixture with filler such as lactose; binders such as starches; and/or lubricants such as talc or magnesium stearate, and stabilizers.
- the active compounds are preferably dissolved or suspended in suitable liquids, such as fats and oils or liquid paraffin, which may be stabilized by addition of stabilizers.
- Formulations suitable for parenteral administration include aqueous solutions of the active compounds, such as water-soluble salt solutions and alkaline solutions. Additionally, appropriate oily injection suspensions of the active compounds may be administered. Suitable lipophilic solvents or vehicles include oils and fats such as sesame oils, synthetic fatty acid esters such as ethyl oleate or triglycerides or polyethylene glycol 400, or hydrogenated castor oil, or cyclodextrins. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, and/or dextran. Suspension stabilizers may also be included.
- the compounds of the present invention are used in topical and parenteral formulations and for the treatment of skin cancer.
- the external preparation of the present invention can be formulated into an oil preparation, a cream preparation, an emulsion preparation, an ointment and the like by preferably suitable carriers.
- suitable carriers include vegetable or mineral oils, white mineral oil (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohols (greater than C12 ).
- Preferred carriers are those in which the active ingredient can be dissolved.
- Emulsifiers, stabilizers, humectants and antioxidants may also be included, as well as, if desired, agents imparting color or fragrance.
- these external preparations may contain transdermal penetration enhancers. Examples of such enhancers can be found in US Pat. Nos. 3,989,816 and 4,444,762.
- Creams are preferably formulated with a mixture of mineral oil, self-emulsifying beeswax and water, in admixture with the active ingredient dissolved in a small amount of oil such as almond oil.
- a typical example of a cream includes about 40 parts water, 20 parts beeswax, 40 parts mineral oil and 1 part almond oil.
- the ointment can be formulated by mixing a vegetable oil containing the active ingredient, such as almond oil, with warm soft paraffin, and then allowing the mixture to cool.
- a vegetable oil containing the active ingredient such as almond oil
- warm soft paraffin a vegetable oil containing the active ingredient
- a typical example of an ointment includes about 30% by weight almond oil and 70% by weight white soft paraffin.
- the present invention also relates to the use of the compounds of the present invention for the preparation of medicaments for the treatment and prevention of NUAK1/2 mediated diseases, disorders and clinical conditions.
- medicaments may include the pharmaceutical compositions described above.
- Examples 3-4 were prepared by a synthetic method similar to that of Example 2.
- Examples 6-19 were prepared using a synthetic method similar to that of Examples 2 and 5.
- Examples 20-24 were prepared using a synthetic method similar to that of Example 19.
- Examples 32-33 were prepared using a synthetic method similar to that of Example 2.
- Example 37 was prepared using a synthetic method similar to that of Example 36.
- Table 1 summarizes the inhibitory effect ( IC50 ) of the NUAK2 enzymatic activity of the compounds of the present invention.
- IC50 inhibitory effect
- Example 1 2 3 4 5 6 IC50 ++ +++ + ++ ++++ +++ Example 7 8 9 10 11 12 IC50 ++ + + +++ ++ ++ Example 13 14 15 16 19 20 IC50 + ++ + ++ ++++ +++ Example twenty one twenty two twenty three twenty four 25 26 IC50 ++ ++++ ++ +++ +++ Example 27 28 29 30 31 32 IC50 ++ +++ +++ +++ +++ Example 33 34 35 36 37 HTH-02-006 IC50 ++ +++ +++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++
- HEC-1-B cells Human endometrial cancer cells HEC-1-B cells were cultured and passaged in complete medium (MEM medium + 10% FBS) after recovery. When the cell confluence reaches about 80%, gently blow the cells away from the bottom of the culture dish with a 1 mL pipette, collect the cell suspension, and centrifuge at 500 rpm for 3 min; discard the supernatant, add complete medium to resuspend the cells, and press Appropriate proportions were inoculated into petri dishes and placed in a 37°C, 5% CO 2 incubator for static culture. The cells were cultured and passaged until the growth state was good and the degree of confluency was about 80%, and the experiment was started.
- MEM medium + 10% FBS complete medium
- a dose-response curve was obtained by fitting a nonlinear S-curve regression using XLFit software to the data, and IC50 values were calculated therefrom.
- Example 2 5 6 10 19 20 IC50 ++ +++ +++ +++ +++ + Example twenty one twenty two twenty three twenty four 26 27 IC50 ++++ + ++++ +++ ++ Example 28 29 32 IC50 ++ +++ ++
Abstract
Description
实施例 | 1 | 2 | 3 | 4 | 5 | 6 |
IC 50 | + | +++ | ++ | ++ | ++ | ++ |
实施例 | 7 | 8 | 9 | 10 | 11 | 12 |
IC 50 | + | + | + | ++ | ++ | ++ |
实施例 | 13 | 14 | 15 | 16 | 19 | 20 |
IC 50 | + | ++ | ++ | + | +++ | +++ |
实施例 | 21 | 22 | 23 | 24 | 25 | 26 |
IC 50 | +++ | ++++ | +++ | ++ | + | +++ |
实施例 | 27 | 28 | 29 | 30 | 31 | 32 |
IC 50 | ++ | ++ | +++ | ++ | ++ | +++ |
实施例 | 33 | 34 | 35 | 36 | 37 | HTH-02-006 |
IC 50 | ++ | +++ | +++ | + | + | +++ |
实施例 | 1 | 2 | 3 | 4 | 5 | 6 |
IC 50 | ++ | +++ | + | ++ | ++++ | +++ |
实施例 | 7 | 8 | 9 | 10 | 11 | 12 |
IC 50 | ++ | + | + | +++ | ++ | ++ |
实施例 | 13 | 14 | 15 | 16 | 19 | 20 |
IC 50 | + | ++ | + | ++ | ++++ | +++ |
实施例 | 21 | 22 | 23 | 24 | 25 | 26 |
IC 50 | ++ | ++++ | ++ | +++ | ++ | +++ |
实施例 | 27 | 28 | 29 | 30 | 31 | 32 |
IC 50 | ++ | +++ | +++ | + | ++ | +++ |
实施例 | 33 | 34 | 35 | 36 | 37 | HTH-02-006 |
IC 50 | ++ | +++ | +++ | ++ | ++ | ++ |
实施例 | 2 | 5 | 6 | 10 | 19 | 20 |
IC 50 | ++ | +++ | +++ | +++ | +++ | + |
实施例 | 21 | 22 | 23 | 24 | 26 | 27 |
IC 50 | ++++ | + | ++++ | +++ | +++ | ++ |
实施例 | 28 | 29 | 32 | |||
IC 50 | ++ | +++ | ++ |
Claims (10)
- 式I的化合物,或其药学上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、同位素标记化合物、溶剂化物、水合物或前药:其中,环A为可被取代的杂环基或杂芳基;优选地,R 0连接在环A与含B 1-B 3的环所桥接的环碳原子的邻位;R 0选自任选取代的碳环基和任选取代的杂环基;B 1选自N和CR 1;B 2选自N和CR 2;B 3选自N和CR 3;D 1选自N和CR 4;D 2选自N和CR 5;D 3选自N和CR 6;R 1、R 2、R 3、R 4、R 5和R 6各自独立选自H、卤素、任选取代的烷基和任选取代的烷氧基;R 7选自卤素、任选取代的C 1-C 6烷基和任选取代的C 1-C 6烷氧基;R 8选自任选取代烷基、任选取代的烷氧基、任选取代的氨基、任选取代的杂环基和任选取代的杂芳基;或R 8与D 1或与D 2连接形成任选取代的杂环基或杂芳基。
- 如权利要求1或2所述的化合物,或其药学上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、同位素标记化合物、溶剂化物、水合物或前药,其中,所述化合物具有下述一项或任意多项特征:(1)R 0为任选取代的C 3-C 7环烷基、任选取代的C 3-C 7环烯基或任选取代的3-7元杂环基;优选地,所述杂环基为3-6元含氮和/或氧的杂环基,包括氮杂环丁基、氧杂环丁基、氧杂环丙基、四氢呋喃基、四氢吡喃基、吡咯烷基、吗啉基、哌嗪基和哌啶基;优选地,被取代时,R 0的取代基数量为1、2或3个,取代基选自卤素、C 1-C 6烷基、卤代C 1-C 6烷基、羟基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基和-NR aR b,其中,R a和R b各自独立为H或C 1-C 4烷基;(2)B 1为N或CR 1,B 2为N,B 3为N或CR 3;R 1优选为H、卤素或C 1-C 4烷基,R 3优选为H、卤素或C 1-C 4烷基;优选地,B 1为N;B 2为N;B 3为CR 3,其中,R 3为H或C 1-C 4烷基;更优选地,B 1为N;B 2为N;B 3为CH;(3)D 1、D 2和D 3各自独立为N或CH;或者D 1为CR 4、D 2为CR 5、D 3为CR 6;优选地,R 4、R 5和R 6各自独立为H、卤素和C 1-C 4烷基;更优选地,D 1、D 2和D 3均为CH;(4)R 7为卤素、任选取代的C 1-C 3烷基或任选取代的C 1-C 3烷氧基;优选地,所述C 1-C 3烷基和C 1-C 3烷氧基被取代时,取代基的数量为1、2、3、4或5个,取代基独立选自卤素、羟基和-NR aR b,其中,R a和R b各自独立为H或C 1-C 4烷基;优选地,R 7为卤素、C 1-C 3烷氧基或卤代C 1-C 3烷氧基;(5)R 8为任选取代的C 1-C 6烷基、任选取代的C 1-C 6烷氧基、任选取代的C 1-C 6烷基氨基和任选取代的4-7元含氮和/或氧的杂环基,包括氮杂环丁基、氧杂环丁基、四氢呋喃基、四氢吡喃基、吡咯烷基、吗啉基、哌嗪基、1,4-二氮杂环庚烷基和哌啶基;优选地,R 8上的取代基是1-4个选自以下的基团:C 1-C 6烷基、羟基取代的C 1-C 6烷基、卤代C 1-C 6烷基、C 1-C 6烷氧基、C 1-C 6酰基、任选地被1-4个C 1-C 6烷基取代的杂环基、卤素、-NR aR b和羟基,其中,R a和R b各自独立为H和C 1-C 6烷基;优选地,R 8为任选被1或2个选自-NR aR b、C 1-C 4烷基和卤代C 1-C 4烷基的取代基取代的4-7元含氮杂环基,包括氮杂环丁基、吡咯烷基、哌嗪基、1,4-二氮杂环庚烷基和哌啶基。
- 如权利要求1所述的化合物,或其药学上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、同位素标记化合物、溶剂化物、水合物或前药,其中,所述式I化合物具有下式IIa、IIb或IIc所示的结构:其中,R 0、B 1、B 2、B 3、D 1、D 2、D 3、R 7和R 8如权利要求1或3所述;A 1选自N和CR 9;A 2选自N和CR 10;A 3选自O、S、NR 11和CR 13R’ 13;A 4选自O、S、NR 12和CR 14R’ 14;R 9和R 10各自独立为H、卤素、氰基、可被任选取代的C 1-C 6烷基、可被任选取代的C 1-C 6烷氧基或可被任选取代的C 1-C 6酰基;R 11和R 12各自独立为H或可被任选取代的C 1-C 6烷基;R 13、R’ 13、R 14和R’ 14各自独立为H、可被任选取代的C 1-C 6烷基或可被任选取代的C 1-C 6烷氧基。
- 如权利要求1所述的化合物,或其药学上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、同位素标记化合物、溶剂化物、水合物或前药,其中,所述式I化合物具有下式结构式:其中,各结构式中,R 0、B 1、B 2、B 3、R 7如权利要求1或3所述;R 9、R 10和R 12如权利要求4或5所述;Cy选自任选取代的杂环基;优选地,Cy为任选取代的4-7元含氮和/或氧的杂环基,包括氮杂环丁基、氧杂环丁基、四氢呋喃基、四氢吡喃基、吡咯烷基、吗啉基、哌嗪基、1,4-二氮杂环庚烷-1-基和哌啶基;优选地,被取代时,Cy的取代基数量为1、2或3个,取代基选自C 1-C 6烷基、羟基取代的C 1-C 6烷基、卤代C 1-C 6烷基、C 1-C 6烷氧基、C 1-C 6酰基、任选地被1-4个C 1-C 6烷基取代的杂环基、卤素、-NR aR b和羟基,其中,R a和R b各自独立为H和C 1-C 6烷基;更优选地,Cy为任选被1-3个选自C 1-C 6烷基和羟基取代的C 1-C 6烷基的取代基取代的哌嗪基,任选被1个选自C 1-C 6烷基和-NR aR b的取代基取代的哌啶基,任选被1-3个C 1-C 6烷基取代的1,4-二氮杂环庚烷-1-基和任选被1-3个C 1-C 6烷基取代的吗啉基;其中,R a和R b独自选自H和C 1-C 4烷基。
- 权利要求1的化合物,或其药学上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、同位素标记化合物、溶剂化物、水合物或前药,其中,所述化合物选自:8-环戊基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)蝶啶-7(8H)-酮;1-环戊基-7-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-3,4-二氢嘧啶并[4,5-d]嘧啶-2(1H)-酮;1-环丙基-7-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-3,4-二氢嘧啶并[4,5-d]嘧啶-2(1H)-酮;1-环戊基-7-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-3-甲基-3,4-二氢嘧啶并[4,5-d]嘧啶-2(1H)-酮;1-环戊基-7-(((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)嘧啶并[4,5-d]嘧啶-2(1H)-酮;1-环己基-7-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)嘧啶并[4,5-d]嘧啶-2(1H)-酮;1-环戊基-7-((2-乙氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)嘧啶并[4,5-d]嘧啶-2(1H)-酮;1-环戊基-7-((2-异丙氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)嘧啶并[4,5-d]嘧啶-2(1H)-酮;1-环戊基-7-((4-(4-甲基哌嗪-1-基)-2-(三氟甲氧基)苯基)氨基)嘧啶并[4,5-d]嘧啶-2(1H)-酮;1-环戊基-7-((2-甲基-4-(4-甲基哌嗪-1-基)苯基)氨基)嘧啶并[4,5-d]嘧啶-2(1H)-酮;7-((2-氯-4-(4-甲基哌嗪-1-基)苯基)氨基)-1-环戊基嘧啶并[4,5-d]嘧啶-2(1H)-酮;7-((2-溴-4-(4-甲基哌嗪-1-基)苯基)氨基)-1-环戊基嘧啶并[4,5-d]嘧啶-2(1H)-酮;1-环戊基-7-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-5-甲基嘧啶并[4,5-d]嘧啶-2(1H)-酮;1-环丁基-7-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)嘧啶并[4,5-d]嘧啶-2(1H)-酮;1-环丙基-7-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)嘧啶并[4,5-d]嘧啶-2(1H)-酮;7-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-1-(四氢-2H-吡喃-4-基)嘧啶并[4,5-d]嘧啶-2(1H)-酮;7-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-1-(哌啶-4-基)嘧啶并[4,5-d]嘧啶-2(1H)-酮;7-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-1-(1-甲基哌啶-4-基)嘧啶并[4,5-d]嘧啶-2(1H)-酮;8-环戊基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)吡啶并[2,3-d]嘧啶-7(8H)-酮;8-环戊基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-6-甲基吡啶并[2,3-d]嘧啶-7(8H)-酮;8-环丙基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-6-甲基吡啶并[2,3-d]嘧啶-7(8H)-酮;8-环己基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)吡啶并[2,3-d]嘧啶-7(8H)-酮;8-环丙基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)吡啶并[2,3-d]嘧啶-7(8H)-酮;5-环戊基-3-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)吡啶并[2,3-e][1,2,4]三嗪-6(5H)-酮;1-环戊基-7-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-2-氧代-1,2-二氢-1,6-萘啶-3-甲腈;8-环戊基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-6-甲腈;8-环戊基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-5-甲基吡啶并[2,3-d]嘧啶-7(8H)-酮;8-环戊基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-5,8-二氢吡啶并[2,3-d]嘧啶-7(6H)-酮;8-环己基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-5,8-二氢吡啶并[2,3-d]嘧啶-7(6H)-酮;8-环丙基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-5,8-二氢吡啶并[2,3-d]嘧啶-7(6H)-酮;8-环戊基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-6H-嘧啶并[5,4-b][1,4]恶嗪-7(8H)-酮;7-((2-溴-4-(4-甲基哌嗪-1-基)苯基)氨基)-1-环戊基-3,4-二氢嘧啶并[4,5-d]嘧啶-2(1H)-酮;7-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-1-(四氢-2H-吡喃-4-基)-3,4-二氢嘧啶[4,5-d]嘧啶-2(1H)-酮;8-环戊基-N-(2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)吡啶并[4,3-d]嘧啶-2-胺;8-(环戊-1-烯-1-基)-N-(2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)吡啶并[4,3-d]嘧啶-2-胺;6-乙酰基-8-环戊基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-5-甲基吡啶并[2,3-d]嘧啶-7(8H)-酮;6-乙酰基-8-环戊基-2-((2-甲氧基-4-(哌嗪-1-基)苯基)氨基)-5-甲基吡啶并[2,3-d]嘧啶-7(8H)-酮;8-环己基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-6-甲基吡啶并[2,3-d]嘧啶-7(8H)-酮;8-环丁基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-6-甲基吡啶并[2,3-d]嘧啶-7(8H)-酮;8-环庚基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)-6-甲基吡啶并[2,3-d]嘧啶-7(8H)-酮;8-环庚基-2-((2-甲氧基-4-(4-甲基哌嗪-1-基)苯基)氨基)吡啶并[2,3-d]嘧啶-7(8H)-酮。
- 权利要求1~7中任一项所述的化合物或其药学上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、同位素标记化合物、溶剂化物、水合物或前药在制备治疗或预防NUAK1/2介导的疾病、障碍和病症的药物中的用途;优选地,所述疾病、障碍和病症是癌症;更优选地,所述癌症选自肝癌、黑素瘤、霍奇金病、非霍奇金淋巴瘤、急性淋巴白血病、慢性淋巴白血病、多发性骨髓瘤、成神经细胞瘤、乳腺癌、卵巢癌、维尔姆斯瘤、子***、睾丸癌、软组织肉瘤、原发性巨球蛋白血症、膀胱癌、慢性粒细胞白血病、原发性脑癌、恶性黑素瘤、非小细胞肺癌、小细胞肺癌、胃癌、结肠癌、恶性胰腺胰岛瘤、恶性类癌性癌症、绒毛膜癌、蕈様肉芽腫、头颈癌、骨原性肉瘤、胰腺癌、急性粒细胞白血病、毛细胞白血病、横纹肌肉瘤、卡波西肉瘤、泌尿生殖***肿瘤病、甲状腺癌、食管癌、恶性高钙血症、子宫颈增生症、肾细胞癌、子宫内膜癌、真性红细胞增多症、特发性血小板增多症、肾上腺皮质癌、皮肤癌和***癌;优选地,所述药物与放射治疗联用。
- 如权利要求8所述的用途,其中,所述药物还包括至少一种已知的抗癌药物或所述抗癌药物的可药用盐;优选地,所述抗癌药物选自下组中的一种或多种:白消安、马法兰、苯丁酸氮芥、环磷酰胺、异环磷酰胺、替莫唑胺、苯达莫司汀、顺铂、丝裂霉素C、博莱霉素、卡铂、喜树碱、伊立替康、托泊替康、阿霉素、表阿霉素、阿克拉霉素、米托蒽醌、甲基羟基玫瑰树碱、铭托泊普、5-氮杂胞苷、吉西他滨、5-氟尿嘧啶、甲氨蝶呤、5-氟-2′-去氧尿苷、氟达拉滨、奈拉滨、阿糖胞苷、普拉曲沙、培美曲塞、羟基脲、硫代鸟嘌呤、秋水仙碱、长春碱、长春新碱、长春瑞滨、紫杉醇、伊沙匹隆、卡巴他赛、 多西他赛、单抗、帕尼单抗、耐措妥珠单抗、纳武单抗、派姆单抗、雷莫芦单抗、贝伐珠单抗、帕妥珠单抗、曲妥珠单抗、西妥昔单抗、奥滨尤妥珠单抗、奥法木单抗、利妥昔单抗、阿仑单抗、替伊莫单抗、托西莫单抗、本妥昔单抗、达雷木单抗、埃罗妥珠单抗、T-DM1、Ofatumumab、Dinutuximab、Blinatumomab、易普利姆玛、阿瓦斯丁、赫赛汀、美罗华、伊马替尼、吉非替尼、厄洛替尼、奥斯替尼、阿法替尼、赛立替尼、艾乐替尼、克唑替尼、埃罗替尼、拉帕替尼、索拉非尼、舒尼替尼、尼罗替尼、达沙替尼、帕唑帕尼、特癌适、依维莫司、伏立诺他、罗咪地辛、帕比司他、贝利司他、他莫昔芬、来曲唑、氟维司群、米托胍腙、奥曲肽、视黄酸、砒霜、唑来膦酸、硼替佐米、卡非佐米、Ixazomib、维莫德吉、索尼德吉、狄诺塞麦、萨力多胺、来那度胺、Venetoclax、Aldesleukin(重组人白介素-2)、Sipueucel-T(***癌治疗疫苗)、帕博西尼、奥拉帕尼、niraparib,rucaparib、talazoparib、pamiparib、fluzoparib和Senaparib。
- 一种药用组合物,包括权利要求1~7中任一项所述的化合物或其药学上可接受的盐、几何异构物、对映异构物、非对映异构物、外消旋物、同位素标记化合物、溶剂化物、水合物或前药与可药用载体;优选地,所述药用组合物还含有至少一种已知的抗癌药物或所述抗癌药物的可药用盐;优选地,所述至少一种已知的抗癌药物选自下组:白消安、马法兰、苯丁酸氮芥、环磷酰胺、异环磷酰胺、替莫唑胺、苯达莫司汀、顺铂、丝裂霉素C、博莱霉素、卡铂、喜树碱、伊立替康、托泊替康、阿霉素、表阿霉素、阿克拉霉素、米托蒽醌、甲基羟基玫瑰树碱、铭托泊普、5-氮杂胞苷、吉西他滨、5-氟尿嘧啶、甲氨蝶呤、5-氟-2′-去氧尿苷、氟达拉滨、奈拉滨、阿糖胞苷、普拉曲沙、培美曲塞、羟基脲、硫代鸟嘌呤、秋水仙碱、长春碱、长春新碱、长春瑞滨、紫杉醇、伊沙匹隆、卡巴他赛、多西他赛、单抗、帕尼单抗、耐措妥珠单抗、纳武单抗、派姆单抗、雷莫芦单抗、贝伐珠单抗、帕妥珠单抗、曲妥珠单抗、西妥昔单抗、奥滨尤妥珠单抗、奥法木单抗、利妥昔单抗、阿仑单抗、替伊莫单抗、托西莫单抗、本妥昔单抗、达雷木单抗、埃罗妥珠单抗、T-DM1、Ofatumumab、Dinutuximab、Blinatumomab、易普利姆玛、阿瓦斯丁、赫赛汀、美罗华、伊马替尼、吉非替尼、厄洛替尼、奥斯替尼、阿法替尼、赛立替尼、艾乐替尼、克唑替尼、埃罗替尼、拉帕替尼、索拉非尼、舒尼替尼、尼罗替尼、达沙替尼、帕唑帕尼、特癌适、依维莫司、伏立诺他、罗咪地辛、帕比司他、贝利司他、他莫昔芬、来曲唑、氟维司群、米托胍腙、奥曲肽、视黄酸、砒霜、唑来膦酸、硼替佐米、卡非佐米、Ixazomib、维莫德吉、索尼德吉、狄诺塞麦、萨力多胺、来那度 胺、Venetoclax、Aldesleukin、Sipueucel-T、帕博西尼、奥拉帕尼、niraparib,rucaparib、talazoparib、pamiparib、fluzoparib和senaparib。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/255,476 US20240124464A1 (en) | 2020-12-02 | 2021-11-29 | Substituted fused bicyclic compound as kinase inhibitor and use thereof |
CN202180081181.3A CN116529251A (zh) | 2020-12-02 | 2021-11-29 | 取代的稠合双环化合物作为激酶抑制剂及其应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011414870.5 | 2020-12-02 | ||
CN202011414870 | 2020-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022116943A1 true WO2022116943A1 (zh) | 2022-06-09 |
Family
ID=81852942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/134071 WO2022116943A1 (zh) | 2020-12-02 | 2021-11-29 | 取代的稠合双环化合物作为激酶抑制剂及其应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20240124464A1 (zh) |
CN (1) | CN116529251A (zh) |
WO (1) | WO2022116943A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4118082A1 (en) * | 2020-03-13 | 2023-01-18 | Prosenestar LLC | Pyrido[2,3-d]pyrimidin-7(8h)-ones as cdk inhibitors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105218561A (zh) * | 2014-06-25 | 2016-01-06 | 上海艾力斯医药科技有限公司 | 稠合嘧啶环衍生物、其制备方法及应用 |
WO2016124160A1 (zh) * | 2015-02-06 | 2016-08-11 | 华东理工大学 | 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 |
-
2021
- 2021-11-29 US US18/255,476 patent/US20240124464A1/en active Pending
- 2021-11-29 WO PCT/CN2021/134071 patent/WO2022116943A1/zh active Application Filing
- 2021-11-29 CN CN202180081181.3A patent/CN116529251A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105218561A (zh) * | 2014-06-25 | 2016-01-06 | 上海艾力斯医药科技有限公司 | 稠合嘧啶环衍生物、其制备方法及应用 |
WO2016124160A1 (zh) * | 2015-02-06 | 2016-08-11 | 华东理工大学 | 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 |
Non-Patent Citations (1)
Title |
---|
D. PERUMAL, P.-Y. KUO, V. V. LESHCHENKO, Z. JIANG, S. K. A. DIVAKAR, H. J. CHO, A. CHARI, J. BRODY, M. V. R. REDDY, W. ZHANG, E. P: "Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma", CANCER RESEARCH, vol. 76, no. 5, 1 March 2016 (2016-03-01), US , pages 1225 - 1236, XP055714644, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-15-2934 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4118082A1 (en) * | 2020-03-13 | 2023-01-18 | Prosenestar LLC | Pyrido[2,3-d]pyrimidin-7(8h)-ones as cdk inhibitors |
EP4118082A4 (en) * | 2020-03-13 | 2024-05-01 | Prosenestar Llc | PYRIDO[2,3-D PYRIMIDIN-7(8H)-ONE AS CDK INHIBITORS |
Also Published As
Publication number | Publication date |
---|---|
CN116529251A (zh) | 2023-08-01 |
US20240124464A1 (en) | 2024-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6698799B2 (ja) | Fgfr抑制剤としての二環式複素環 | |
RU2747260C2 (ru) | Ингибитор рфрф4, способ его получения и его фармацевтическое применение | |
KR102558066B1 (ko) | Tam 억제제로서 피롤로트리아진 화합물 | |
JP6876833B2 (ja) | Fgfr阻害剤およびその使用 | |
WO2018090939A1 (zh) | 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物 | |
EP3997087A1 (en) | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | |
KR102660196B1 (ko) | 치환된 축합 헤테로아릴기 화합물인 키나제 억제제 및 이의 응용 | |
CN110914277B (zh) | 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用 | |
WO2022199652A1 (en) | Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof | |
WO2023025307A1 (en) | Substituted tricyclic compounds as parp inhibitors and use thereof | |
WO2023169226A1 (en) | Substituted tricyclic compounds as parp inhibitors and the use thereof | |
CN110312717B (zh) | 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用 | |
CN114502559B (zh) | 二氢咪唑并嘧啶并嘧啶酮类化合物 | |
WO2022116943A1 (zh) | 取代的稠合双环化合物作为激酶抑制剂及其应用 | |
WO2023066299A1 (en) | Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof | |
WO2022253188A1 (en) | Nitrogen-containing fused heteroaromatic bicyclic compounds as usp1 inhibitors and the use thereof | |
WO2022218296A1 (en) | Substituted fused bicyclic compounds as parp inhibitors and the use thereof | |
WO2024083237A1 (en) | Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof | |
AU2020344050A1 (en) | Substituted imidazoquinoxaline compounds and uses thereof | |
WO2021004482A1 (zh) | 取代的吡唑并喹唑啉酮化合物及其应用 | |
CN116670134A (zh) | 取代的咪唑并[1,5-b]哒嗪化合物作为激酶抑制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21899974 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18255476 Country of ref document: US Ref document number: 202180081181.3 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21899974 Country of ref document: EP Kind code of ref document: A1 |